Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report

Despite advances in therapy, ovarian cancer remains the most lethal gynecological malignancy and prognosis has not substantially improved over the past 3 decades. Immunotherapy is a promising new treatment option. However, the immunosuppressive cancer microenvironment must be overcome for immunother...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 8; p. 562
Main Authors Roelofsen, Thijs, Wefers, Christina, Gorris, Mark A J, Textor, Johannes C, Massuger, Leon F A G, de Vries, I Jolanda M, van Altena, Anne M
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 29.11.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite advances in therapy, ovarian cancer remains the most lethal gynecological malignancy and prognosis has not substantially improved over the past 3 decades. Immunotherapy is a promising new treatment option. However, the immunosuppressive cancer microenvironment must be overcome for immunotherapy to be successful. Here, we present a unique case of spontaneous regression of ovarian carcinoma after septic peritonitis. A 79-year-old woman was diagnosed with stage IIIc ovarian cancer. The omental cake biopsy was complicated by sepsis. Although the patient recovered, her physical condition did not allow further treatment for her ovarian cancer. After 6 months, spontaneous regression of the tumor was observed during surgery. Analysis of the immune infiltrate in the tissues showed a shift from a pro-tumorigenic to an anti-tumorigenic immune response after sepsis. Strong activation of the immune system during sepsis overruled the immunosuppressive tumor microenvironment and allowed for a potent anti-tumor immune response. More understanding of immunological responses in cases with cancer and septic peritonitis might be crucial to identify potential new targets for immunotherapy.
Bibliography:This article was submitted to Women's Cancer, a section of the journal Frontiers in Oncology
Edited by: Paola Gehrig, University of North Carolina at Chapel Hill, United States
Reviewed by: Dayanidhi Raman, University of Toledo, United States; Saori Furuta, University of Toledo, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2018.00562